Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of MINT91 in combination with gemcitabine for advanced solid tumors
jRCT2031240713Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MINT91 and gemcitabine in Nonhematologic neoplasms and ovarian cancer, sponsored by Chugai Pharmaceutical Co., Ltd. Started Apr 2025; status: recruiting.
02
Drugs
MINT91gemcitabine
03
Conditions
Nonhematologic neoplasmsovarian cancer
Beyond the preview
Go deeper on jRCT2031240713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240713.